Weight Loss & Metabolic Health. Retatrutide is a first-in-class triple hormone receptor agonist activating GLP-1, GIP, and glucagon receptors simultaneo...
Retatrutide is a first-in-class triple hormone receptor agonist activating GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, Phase II data showed up to 24% body weight reduction at 48 weeks — exceeding both semaglutide and tirzepatide. It represents the next frontier in metabolic therapeutics.
Retatrutide's triple agonist mechanism targets three metabolic pathways. GLP-1 reduces appetite and slows gastric emptying. GIP enhances insulin secretion and fat metabolism. Glucagon receptor activation increases energy expenditure and hepatic fat oxidation. The combination produces additive or synergistic effects exceeding dual agonist approaches.
Important: The evidence base for Retatrutide varies by application. Many findings are from preclinical (animal or in vitro) studies. Large-scale human clinical trials may not be completed. Always evaluate the quality of evidence before drawing conclusions.
GI effects predominate: nausea, diarrhea, vomiting, decreased appetite — generally mild-to-moderate and diminish over time. The glucagon component may theoretically increase hyperglycemia risk in non-diabetics, though not observed clinically at therapeutic doses.
Retatrutide is investigational, currently in Phase III trials. Not FDA-approved for any indication. Research-grade compound available from some suppliers for laboratory use only.
These verified suppliers carry Retatrutide with third-party COAs and US-based shipping.